Reposicionamento de fármacos na doença de Parkinson: anti-inflamatórios não esteroides como potenciais fármacos para minimizar a neurodegeneração.

Abstract

According to the World Health Organization, neurological disorders such as Parkinson's disease (PD) account for more than 6% of the disease global burden. PD, discovered more than 200 years ago, is characterized by the progressive loss of dopaminergic neurons of the Substantia Nigra pars compacta (SNpc), causing an abnormality in movement control. Several factors may culminate in neurodegeneration, among them evidence suggests that neuroinflammation plays an important role. Although brain inflammatory response is potentially beneficial, recent studies suggest that it can cause progressive degeneration of dopaminergic neurons. Thus, in order to delay the neurodegenerative process, the repositioning of non-steroidal anti-inflammatory drugs (NSAIDs) to treat PD has been investigated. This study analyzed bibliographies referring to the subject in order to verify if NSAIDs produce positive results in the reduction of neurodegeneration in PD.